Document is current
Any future updates will be listed below
-
Authors
Nakaya, Yosuke https://orcid.org/0000-0003-3337-1599
Nakamae, Hirohisa https://orcid.org/0000-0003-4203-990X
Sugita, Junichi https://orcid.org/0000-0003-3852-5075
Kanda, Junya https://orcid.org/0000-0002-6704-3633
Hasegawa, Yuta https://orcid.org/0000-0002-9925-2093
Eto, Tetsuya https://orcid.org/0000-0002-2630-493X
Fukuda, Takahiro
Kurita, Naoki https://orcid.org/0000-0002-1283-4307
Hiramoto, Nobuhiro https://orcid.org/0000-0002-0472-6680
Nagafuji, Koji https://orcid.org/0000-0003-4795-121X
Ota, Shuichi https://orcid.org/0000-0002-3631-244X
Asada, Noboru https://orcid.org/0000-0002-0148-644X
Ando, Toshihiko
Kawakita, Toshiro
Akasaka, Takashi https://orcid.org/0000-0002-0131-2570
Mori, Yasuo https://orcid.org/0000-0001-6425-1720
Kamimura, Tomohiko
Onizuka, Makoto https://orcid.org/0000-0003-3864-0823
Atsuta, Yoshiko https://orcid.org/0000-0003-4404-2870
Nakasone, Hideki https://orcid.org/0000-0001-5812-9315
- License Information
-
More Information
Article History
Received: 28 September 2025
Accepted: 13 April 2026
First Online: 20 April 2026
Declarations
:
: The study protocol was reviewed and approved by the Ethics Committee of Osaka Metropolitan University Graduate School of Medicine in accordance with the Declaration of Helsinki (approval number: 2024-057).
: All patients included in this study provided written informed consent.
: Hideki Nakasone received subsidies from JCR Pharmaceuticals, Kyowa Kirin, Taiho Pharmaceutical, Santen Pharmaceutical, and TERUMO, and honoraria from MSD, Otsuka Pharmaceutical, Pfizer, Novartis, Takeda Pharmaceutical, Janssen Pharmaceutical, Chugai Pharmaceutical, Sanofi, Meiji Seika Pharma, Bristol Myers Squibb, and Asahi Kasei Pharma. The other authors declare no competing interests.
